Karyopharm announced that top-line data from its Phase 3 SENTRY trial in myelofibrosis is expected in March 20261
The Phase 3 SENTRY trial completed enrollment of 353 patients in September 2025, evaluating selinexor in combination with ruxolitinib compared to ruxolitinib plus placebo in JAK inhibitor-naïve myelofibrosis patients1
U.S. net product revenue for XPOVIO reached approximately $115 million for 2025, with fourth quarter revenue of about $32 million1
Total 2025 revenue reached approximately $145 million1
The company has two major clinical trial readouts anticipated in 2026:
myelofibrosis data in March and Phase 3 XPORT-EC-042 results in endometrial cancer by mid-20261
Karyopharm reported approximately $64 million in cash and investments as of December 31, 2025, with existing liquidity expected to fund operations into the second quarter of 20261
Despite recent stock momentum with a nearly 91% surge over the past six months, the company remains unprofitable with a negative EBITDA of $103.8 million1
Analyst price targets range from $6 to $21, with Piper Sandler maintaining an Overweight rating and $12 price target, and RBC Capital maintaining an Outperform rating with a $19 price target1
Sources:
1. https://www.investing.com/news/company-news/karyopharm-expects-phase-3-trial-data-in-myelofibrosis-by-march-93CH-4441516